ZBIO:NSD-Zenas BioPharma, Inc. Common Stock (USD)

COMMON STOCK | Trading--Inverse Equity |

Last Closing

USD 19

Change

+1.48 (+8.45)%

Market Cap

N/A

Volume

0.11M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-20 )

Largest Industry Peers for Trading--Inverse Equity

Symbol Name Price(Change) Market Cap
SQQQ ProShares UltraPro Short QQQ

+0.07 (+0.90%)

USD 2.33B
BIS ProShares UltraShort Nasdaq Bi..

+0.21 (+1.47%)

USD 3.29M

ETFs Containing ZBIO

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Inverse Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 89.62% 100% F 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 89.62% 100% F 92% A
Trailing 5 Years  
Capital Gain 33.05% 100% F 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 33.05% 100% F 63% D
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike